Light Therapy in Modulating the Clinical Phenotype of Patients With Primary and Comorbid Chronic Insomnia.

NCT ID: NCT05797324

Last Updated: 2023-04-06

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 70 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-11-17
• Study Completion Date: 2023-12-31

Brief Summary

Some evidence indicates that circadian rhythm may play a role in the pathophysiology of insomnia disorder. This single-blind randomized controlled multicentre prospective study aims to evaluate the possible therapeutic effect of light therapy in modulating the clinical phenotype of patients affected by chronic primary and comorbid insomnia, through the modification of the circadian phase.

Detailed Description

Some evidence indicates that circadian rhythm may play a role in the pathophysiology of insomnia disorder. This single-blind randomized controlled multicentre prospective study aims to evaluate the possible therapeutic effect of light therapy in modulating the clinical phenotype of patients affected by chronic primary and comorbid insomnia, through the modification of the circadian phase.

STUDY DESIGN AND METHODS

With regard to the study in question, it should be noted that:

• the study is a prospective multicentre randomized single-blind controlled trial
• the duration of the study is expected to be 3 years with a duration of enrollment of 2 and a half years and a minimum clinical follow-up of 3 months

The study will be divided into two evaluations, an initial evaluation (Time 0, T0) where the patients will be enrolled and all the measurements required before treatment with light therapy will be performed, and a final evaluation after 6 weeks of treatment with light therapy effective or sham (Time 1, T1), where the measurements performed at T0 will be repeated. Both assessments will be performed at the Sleep Medicine outpatient clinic.

TIME T0

• The diagnosis of primary chronic or comorbid insomnia will be made during the semi-structured sleep interview by a physician expert in sleep medicine, according to DSM V criteria, supported by clinical scales (Insomnia Severity Index, Pittsburgh Quality Index). The presence of mood/behavioral disorders or cognitive deficits will also be excluded (Beck, Stai, Mini Mental Scale Examination).
• A home polysomnography will be performed to rule out the presence of sleep apnea disorder or periodic limb movement syndrome during sleep
• Circadian parameters (chronotype, Mid sleep, circadian phase, phase angle) will be evaluated in basal conditions through clinical scales (Morning Eveningness Questionnaire, Light diet), measurement of salivary melatonin using evening 5-point wipes at home (DLMO, Elisa) and the actigraphic registration extended for 7 days.
• The associations between the circadian phase and the various phenotypes of primary or comorbid insomnia will be then evaluated, according to the duration and the severity of insomnia.
• Patients without ocular contraindications will then undergo a Luminotherapy protocol (intermittent blue-enriched light therapy with Luminette 10000 lux equivalent) with morning or evening timing, depending on the circadian phase, or sham treatment (control subgroup; white light <100 lux equivalent).
• Patients will be randomly assigned to one of two conditions (treatment and sham). The randomization list will be generated with a simple randomization method through the use of a "Random number generator" software available at www.regione.emilia-romagna.t/sin_info/generatore. The algorithm used in this site coincides with a Lehmer generator (multiplicative congruential generator). Allocation concealment is guaranteed by a central randomization in a distant and independent location with respect to the recruitment site.

TIME T1

> After 6 consecutive weeks of home light therapy, patients will be re-evaluated with the same somnometry battery used at study entry. Furthermore, the actigraphic monitoring and the dosage of salivary melatonin will be repeated, to evaluate the variations of the circadian phase and of the sleep-wake pattern after light therapy.

Conditions

Insomnia Chronic

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Luminette

Patients without ocular contraindications undergo a Luminotherapy protocol (intermittent blue-enriched light therapy with Luminette 10000 lux equivalent) with morning or evening timing, depending on the circadian phase.

Group Type: EXPERIMENTAL

Luminette

Intervention Type: OTHER

Luminotherapy protocol (intermittent blue-enriched light therapy with Luminette 10000 lux equivalent) with morning or evening timing, depending on the circadian rhythm

Sham

Control group (white light \<100 lux equivalent).

Group Type: SHAM_COMPARATOR

Sham

Intervention Type: OTHER

Sham protocol (white light \<100 lux equivalent).

Interventions

Luminette

Luminotherapy protocol (intermittent blue-enriched light therapy with Luminette 10000 lux equivalent) with morning or evening timing, depending on the circadian rhythm

Intervention Type: OTHER

Sham

Sham protocol (white light \<100 lux equivalent).

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Primary chronic insomnia
• Comorbid chronic insomnia
• Absence of pharmacological therapy of insomnia
• Absence of behavioural and cognitive treatment of insomnia
• Capacity to understand the study and adhere to the procedures
• Written informed consent

Exclusion Criteria

• Secondary insomnia due to medical conditions or drug treatment
• Cerebral diseases
• Invalidating diseases
• Eye diseases that contraindicate the use of light therapy
• Psychiatric disorders
• Cognitive decline
• Working in night shifts during the last month before enrolment
• Impossibility to provide informed consent

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

IRCCS National Neurological Institute "C. Mondino" Foundation

OTHER

Sponsor Role: collaborator

Ente Ospedaliero Cantonale, Ticino, Switzerland

OTHER

Sponsor Role: collaborator

Istituto Auxologico Italiano

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Istituto Auxologico Italiano

Oggebbio, , Italy

Site Status: RECRUITING

Countries

Italy

Central Contacts

Riccardo Cremascoli

Role: CONTACT

r.cremascoli@auxologico.it

+393497292068

Facility Contacts

Riccardo Cremascoli, MD

Role: primary

r.cremascoli@auxologico.it

Other Identifiers

21A011

Identifier Type: -

Identifier Source: org_study_id